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ABSTRACT A murine monoclonal antibody (mAb)
against porcine von Willebrand factor (vWF) induced an
antithrombotic state in normal pigs. Thrombosis was induced
by a standard procedure of stenosis and mechanical injury of
the artery. The mAb was an IgG1 K that inhibited vWF-
induced platelet aggregation at a titer of 1:6250 and bound to
immobilized vWF at a maximal dilution of 1:512,000. The
antibody did not affect two other vWF functions, platelet
adhesion and binding of coagulant factor VIII (factor VIII:C).
The antithrombotic state was characterized by a prolonged
bleeding time and lack of plasma vWF activity, but with
near-normal levels of factor VIII:C and von Willebrand
antigen. The circulating Ag-mAb complex demonstrated a
multimeric distribution comparable to that of native plasma
vWF. Three groups of pigs were studied: group A consisted of
nine untreated animals, eight of which developed occlusive
coronary thrombosis; group B, four treated animals with a long
bleeding time, none of which developed occlusive thrombosis;
and group C, two animals with preexisting thrombosis treated
with mAb, in which stable blood flow was reestablished.
Morphologically, the group B animals showed adherent plate-
lets covering the injured intima but no thrombosis. This mAb
is an antithrombotic agent that prevents platelet thrombosis
without affecting intrinsic platelet function.
Thrombus formation in arteries is a multifactorial process. It
includes injury to the vessel wall, local alterations in blood
flow, platelet adhesion to the intima, and formation of the
thrombus proper, with aggregated platelets being a major
component. One model for induction of acute coronary
arterial thrombosis utilizes constriction of the vessel to
produce stenosis, followed by mechanical injury of the wall.
An occlusive thrombus develops at the injury site in this
stenosis/injury (S/I) model (1-3). A major pathway for
recruiting platelets to the buildup of the thrombus appears to
involve the plasma von Willebrand factor (vWF), a macro-
molecular adhesive glycoprotein. vWF is required for platelet
adhesion to exposed subendothelium under high wall shear
rate conditions, with formation of a monolayer of activated
platelets (4, 5). In certain models variable platelet adhesion
does occur without vWF, but the platelets appear not to be
activated (6, 7). The importance of vWF in causing platelet
aggregation is well established when it is induced in vitro with
ristocetin (8) or botrocetin (9) or with ruminant or pig plasmas
with human platelets (10, 11). vWF binds to glycoproteins lb
and Ilb/IlIa in the platelet membrane to form interplatelet
bridges (12). The role ofvWF in platelet thrombus formation
has been investigated in vivo to only a limited extent. In a
study of accelerated atherosclerosis in swine, myocardial
infarction evidently secondary to a coronary thrombus oc-
curred in normal pigs but not in pigs with the same degree of
atherosclerosis that had von Willebrand disease (vWD) (13).
It was recently reported from this laboratory that bleeder pigs
with homozygous vWD, lacking plasma vWF, were protect-
ed from development of acute coronary thrombosis in the S/I
model (3), suggesting an important role of vWF in acute
arterial thrombus formation.
In this study we describe a murine monoclonal antibody
(mAb) that binds to vWF and, when given to normal pigs,
causes a prolonged bleeding time (BT) and depletion of
plasma vWF activity without interfering with vWF-depen-
dent platelet adhesion. In the S/I model, the mAb prevented
acute coronary thrombosis and caused the reestablishment of
stable blood flow in arteries already occluded by thrombi.
These data indicate that platelet thrombosis may be prevent-
ed or alleviated by altering the reactivity ofthe vWF molecule
without interfering with platelet function. A preliminary
report has been published (14).
METHODS
mAb Production. The mAb was prepared as described (15),
using a purified porcine vWF as antigen (Ag) (16). Immuno-
globulin subtype was determined from cell culture superna-
tants by using a commercial kit (Boehringer Mannheim).
Murine ascites fluid was used as the source of mAb.
Experimental Animals. Normal pigs from the closed colony
at the University ofNorth Carolina were used. The standards
set forth in "Guide for the Care and Use of Laboratory
Animals" (National Institutes of Health publication no.
85-23) were followed.
Assays of vWF and Coagulant Factor VIII (Factor VIII:C).
Three functional assays for vWF were performed. The
platelet-agglutinating factor (PAggF) assay, termed vWF/
PAggF, utilized citrated porcine platelet-poor plasma (PPP)
and lyophilized fixed human platelets in a macroscopic
platelet agglutination procedure (17, 18). vWF/botrocetin
and vWF/ristocetin assays were performed as described (19).
Inhibition of vWF-dependent platelet agglutination by mAb
was done with each vWF assay procedure, using a 12-well
glass titer plate and 50 ,ul of each reagent. The test mixtures
for vWF/PAggF inhibition consisted of imidazole-buffered
saline (IBS), pH 7.3 (18), porcine PPP diluted 1:4 with IBS,
and serial 1:5 dilutions with IBS of mAb (1:2). After incuba-
tion for 5 min at 25°C, human platelets (800,000 per ,l) were
added and observed for agglutination at 10 min. The mixture
Abbreviations: Ag, antigen; BT, bleeding time; factor VIII:C,
coagulant factor VIII; IBS, imidazole-buffered saline; mAb, mono-
clonal antibody; PAggF, platelet-agglutinating factor; PPP, platelet-
poor plasma; PRP, platelet-rich plasma; S/I, stenosis/injury; vWD,
von Willebrand disease; vWF, von Willebrand factor; vWF:Ag, von
Willebrand antigen.
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for vWF/botrocetin inhibition consisted of lyophilized por-
cine platelets, porcine PPP, and mAb serially diluted as
above. After incubation, botrocetin (40 units/ml) was added.
The mixtures for vWF/ristocetin inhibition testing consisted
of human platelets, human PPP, and mAb. After incubation,
ristocetin (2.4 mg/ml) was added. von Willebrand antigen
(vWF:Ag) was determined by Laurell electroimmunoassay
(20). Specificity of binding of mAb to porcine vWF was
determined by competitive inhibition ELISA (21).
Factor VIII:C activity was assayed by the partial throm-
boplastin time procedure of Langdell et al. (22), using canine
hemophilic plasma as substrate. mAb inhibition of factor
VIII:C was tested by mixing equal parts of pooled normal
porcine plasma and either IBS or serial dilutions of mAb in
IBS. The factor VIII:C was determined before and after
incubation for 1 hr at 370C.
Other Tests. Tests for mAb inhibition of platelet aggrega-
tion by adenosine diphosphate (ADP; 20 MM), thrombin (2
units/ml), and collagen/MgCl2 (8 mM) were performed in a
Payton aggregometer at 37°C, using 0.3 ml ofporcine platelet-
rich plasma (PRP) (3 x 105 platelets per ,u) and 0.1 ml ofmAb
(1:10) or IBS. After 5-min incubation, 0.1 ml of agonist was
added. mAb inhibition of platelet adhesion to deendothelial-
ized porcine artery surface was tested in a Baumgartner ex
vivo perfusion chamber (23). The ear BT was measured as
described by Mertz (24).
S/I Model of Induced Coronary Artery Thrombosis. The
Folts system (1, 2) modified by Nichols et al. (3) with S/I of
porcine coronary arteries was used. Three experimental
groups of normal pigs were studied. Group A consisted of
nine pigs not treated with mAb. Five of the nine animals
served as controls in another study (3). Group B consisted of
four animals treated with mAb prior to S/I, and group C (two
animals) was treated with mAb after a thrombus had formed.
Mean baseline data for the pigs, treated vs. nontreated, were
as follows: body weight, 29 vs. 31 kg; platelet count, 4.8 vs.
4.1 x 105 per ,ul; plasma vWF/PAggF, 0.99 vs. 1.08 units/ml;
and BT, 3 vs. 2.25 min. Two intravenous injections of mAb
(33 ,u/kg) were given with a 30-min interval between doses,
after placement of the open clamp and Doppler velocity
probe. Platelet count, hematocrit, vWF/PAggF, vWF:Ag,
factor VIII:C, and BT were determined prior to mAb infu-
sion, 5 min after infusion, and at 30-min intervals thereafter
for the duration of the experiment. In group C, a pattern of
cyclic flow reductions was well established after arterial S/I
before administration of mAb. Morphometric analysis of the
extent of injury and thrombosis was performed for all animals
as described (3).
RESULTS
Selection and Some Functional Characteristics of the mAb.
Ten clones were screened for their anti-vWF activity, using
the PAggF test. One clone, BB3 BD5, with high titer
anti-vWF activity was selected for further characterization.
It produced an IgG1 K light chain mAb. The mAb showed
binding to immobilized vWF in an ELISA assay at a maximal
dilution of 1:512,000.
The specificity ofthe mAb binding for porcine plasma vWF
was shown by competitive inhibition ELISA. Plasmas from
normal pigs (1.0 unit ofvWF per ml), vWD carrier pigs (0.56
unit/ml), and vWD severe bleeder pigs (<0.01 unit/ml) were
used. The relative inhibition of mAb binding caused by the
three types of plasmas was dependent on the vWF content of
the plasmas. The greatest degree of inhibition was seen with
normal plasma, while bleeder plasma, with only a trace of
vWF, had a limited effect on antibody binding.
Inhibition of vWF functional activity by the mAb is
demonstrated in Table 1. In each of the three tests for vWF




Test vWF Platelets of mAb
vWF/PAggF Porcine Human 1:10-1:6250
vWF/botrocetin Porcine Porcine 1:10-1:6250
Canine Human 1:10-1:1250
vWF/ristocetin Human Human 1:10-1:6250
activity, the mAb completely inhibited platelet agglutination
at maximal dilutions of 1:1250-1:6250. The mAb to porcine
vWF demonstrated cross-reactivity with both human and
canine vWF. Fig. 1A illustrates complete inhibition of vWF
platelet-agglutinating activity. Fig. 1B illustrates that the
mAb caused rapid and complete platelet deagglutination. The
mAb had no inhibitory effect on aggregation in PRP induced
with the agonists ADP, thrombin, and collagen or on factor
VIII:C activity.
The effect of the mAb on platelet adhesion to porcine
arterial subendothelium is illustrated in Fig. 2. The platelet
adhesion index, that is, the percent of arterial surface area
covered with adherent platelets, with vWD and normal
porcine blood without mAb, was 22% and 79%, respectively.
After in vitro addition ofmAb to normal blood and incubation
for 5 min, the value was 73%. With normal blood/mAb
mixtures incubated for 30 min, the value was 56%. vWF/
PAggF could not be detected in the plasmas from the whole
blood/mAb mixtures, while the vWF:Ag and factor VIII:C
levels were within normal limits. In another study, whole
blood from four normal pigs infused with mAb 30 min earlier
(Table 2, group B) was tested in the Baumgartner chamber.
The platelet adhesion index was 70%. These studies indicate
that the mAb did not inhibit platelet adhesion in this model.
Antithrombotic Effect of mAb. The dose of mAb injected
into the test animals was calculated to reduce plasma vWF
levels to <5% ofnormal and to prolong the BT throughout the
experimental period. Of the seven treated pigs, all pigs but
one were so maintained. Fig. 3A demonstrates the effect of
injected mAb on plasma vWF/PAggF, BT, vWF:Ag, and
factor VIII:C in one animal of group B. Functional plasma
vWF was undetectable, while vWF:Ag and factor VIII:C








FIG. 1. Aggregometry tracings demonstrating effect of mAb on
vWF/PAggF agglutination. A Payton dual-channel aggregometer
was used at 37°C, with a stir rate of 103 rpm. (A) In the upper tracing,
0.2 ml of IBS and 0.1 ml of a suspension of lyophilized human
platelets were stirred in the aggregometer for 60 sec. At the arrow,
0.1 ml of porcine PPP and 10 ,ul of IBS were added simultaneously.
In the lower tracing, 10 ,ul ofmAb (1:10) was substituted for IBS. (B)
At the solid arrow, 0.1 ml of PPP was added. At the open arrow, 10
,ul of mAb was added. Immediate complete deagglutination was
indicated by decreased light transmission and was verified by
phase-contrast microscopy.














































FIG. 2. Effect of mAb on platelet adhesion to subendothelial
surface of porcine arteries. The Baumgartner ex vivo annular
perfusion chamber system (23) was adapted for use with 1-cm
segments of everted normal porcine femoral or carotid arteries.
Citrated whole porcine blood from either three normal or four vWD
animals was perfused across the arterial segment at 130 ml/min, at
a shear rate of 1700 sec-I for 5 min, at 37°C. To test the effect ofmAb,
50 ,l ofmAb was added to 55 ml of citrated normal blood, followed
by incubation for 5 min at 37°C prior to perfusion. The chamber was
flushed with buffer followed by fixation with buffered 4% paraform-
aldehyde. Plastic-embedded cross sections (2 ,m thick) from the
midsection of the perfused arterial segments were evaluated for
platelet adhesion by light microscopy at 10-Im intervals. The results
are expressed as mean percent total surface area of exposed
subendothelium covered with adherent platelets, with range of
values indicated.
of vWF:Ag multimers was still observed in the plasma (Fig.
4). Fig. 3B illustrates the results with one mAb-treated animal
in which the BT prolongation was transient and the
vWF/PAggF recovered to about 10% of normal during the
experiment. The results suggest that the mAb masked the
vWF domain(s) required for platelet aggregation and a normal
BT and that Ag-mAb complexes remained in circulating
plasma.
Table 2 demonstrates the prevention of induced coronary
artery thrombosis by mAb administration. Eight of nine
animals in the nontreated group, A, developed changes in
flow velocity indicative of thrombosis. None of the four
animals in the treated group, B, developed occlusive throm-
bosis, as indicated by lack of change in blood flow velocity.
Morphologic data were in accord with the rheologic findings
(Fig. 5). Comparison of the mAb-treated and untreated
groups indicates statistical significance of the difference
(Table 2). Morphometric analysis by light microscopy of the
coronary arteries of the treated and untreated animals
showed comparable injury to the intima and media. The
animal whose responses are depicted in Fig. 3B, whose BT
returned to normal, developed an occlusive thrombus. This
datum along with previous data (3) indicates the importance
of a prolonged BT as an indicator of the antithrombotic state.
The effect of administering mAb on established coronary
thrombosis was tested in two pigs (group C). In the first pig,
two mAb infusions produced total resolution of the cyclic
flow reductions despite the presence of stenosis. Fig. 6
illustrates the course of the second pig with established
Table 2. Effect of mAb administration on change in coronary
arterial blood flow velocity as an index of thrombosis
No. of mAb No. of animals with
Group animals treatment change in flow velocity
A 9 None 8
B 4 Before S/I 0*
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FIG. 3. Effect of administration of mAb to normal pigs on plasma
vWF/PAggF, BT, vWF:Ag, and factor VIII:C. Arrows indicate time
of mAb injection. (A) Illustrative example of one of the four pigs of
group B with a persistent prolongation of the BT. (B) Data of a pig
with transient prolongation of BT.
thrombosis. After mAb infusion, blood flow stabilized. In the




FIG. 4. Densitometer (LKB Ultrascan XL) scan demonstrating
multimeric composition of vWF:Ag in a plasma sample 30 min after
mAb infusion (see Fig. 3A). Sodium dodecyl sulfate gel electropho-
resis (Laemmli) was performed by the Aihara et al. modification (25)
of the Ruggeri-Zimmerman procedure (26). Left to right, low
molecular weight to high molecular weight multimers. Each species
ofmultimer observed in the preinfusion plasma sample is represented
in this tracing. (Note the tracing is magnified relative to the gel.)
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ually resumed. A second infusion of mAb decreased their
frequency. After mAb infusion in this group of animals, the
BT was prolonged and vWF/PAggF levels were reduced
similar to the level shown in Fig. 3A. Morphologically,
thrombotic material persisted in the coronary arteries of both
animals. These data suggest that the mAb caused deaggrega-
tion of platelets in the thrombus sufficient to permit reestab-
lishment of stable blood flow.
DISCUSSION
These studies demonstrate that inactivation of plasma vWF
in normal pigs by injection of a mAb to porcine vWF protects
them from thrombosis and causes a breakup of established
thrombi. The mAb is an IgG1 K that binds specifically to
plasma vWF, presumably to an epitope that is coincident to
the functional domain responsible for vWF-dependent plate-
let aggregation. The mAb completely prevented vWF-depen-
dent platelet agglutination induced by ristocetin or botrocetin
or in the PAggF test (Table 1). It also caused preformed
aggregates to break up (Fig. 1B). In the latter case, the mAb
apparently can attack the vWF in the interplatelet bridges
within the aggregate by forming Ag-mAb complexes, which
do not retain the adhesive force ofthe native vWF. This mAb
did not interfere with two other functions of the vWF
molecule, platelet adhesion to subendothelium (Fig. 2) and
covalent binding of factor VIII:C.
Many anti-vWF mAbs have been described (27). Several of
these inhibit platelet adhesion but not ristocetin-induced
vWF aggregation of platelets. The majority of these antibod-
ies inhibit both activities. One mAb to human vWF has been
described with characteristics similar to mAb (28).
The antithrombotic state caused by injecting the mAb BB5
to normal pigs (Fig. 3) is similar to an mAb-induced vWD-like
syndrome described earlier, with loss ofplasma vWF activity
and a prolonged BT (29). In keeping with the in vitro studies
of the effect of the mAb on normal plasma, the plasmas of the
treated animals retained the ability to induce platelet adhe-
sion in a Baumgartner chamber and retained their associated
factor VIII:C activity. In contrast to the loss of functional
vWF, the vWF:Ag levels were maintained near normal (Fig.
3).
Densitometer scanning of the gels demonstrating the mul-
timeric structure of the vWF:Ag indicated that the full range
of multimers observed in normal plasma persists after treat-
ment with the mAb (Fig. 4). This suggests that the Ag-mAb
complex has electrophoretic properties similar to those of the
native vWF. While ristocetin and PAggF testing identify only
the higher molecular weight vWF multimers, botrocetin
recognizes a wide spectrum of multimer sizes (30). These
data suggest that the mAb combines with the full spectrum of







FIG. 5. Scanning electron micrograph of intimal surface of
coronary artery segments subjected to S/I after infusion of mAb.
Exposed subendothelium is partially covered with adherent plate-
lets, without thrombus formation. (x2500.)
The experimental design for the study ofmAb treatment on
prevention of thrombosis included maintenance of a pro-
longed BT throughout the experiment. All of the animals that
met this criterion were protected from occlusive thrombosis,
which occurred in 8 of the 9 control animals (P = 0.007)
(Table 2). In the treated animals there was no disturbance in
blood flow, which indicated lack of thrombosis. Morpholog-
ically, the intimal surface of the damaged coronary artery
demonstrated platelet adhesion to exposed subendothelium
but gave no evidence of progression to thrombosis (Fig. 5).
In an earlier study demonstrating lack of thrombosis in
vWD pigs in the S/I thrombosis model, the persistence of a
long BT in transfused animals appeared to be a better
indicator of the antithrombotic state than the plasma vWF
levels (3). In one animal in the present study, the amount of
mAb administered was inadequate to maintain a prolonged
BT throughout the experiment (Fig. 3B). Thrombosis was
induced when the plasma vWF activity increased to about
1o of normal and when the BT was normal.
When a similar thrombosis model in dogs and monkeys was
used, a mAb against the platelet receptor glycoprotein
IIb/IIIa also caused prevention of arterial thrombosis (31).
Fibrinogen binds avidly to glycoprotein Ilb/II1a, and inter-
Infusion
FIG. 6. Restoration of coronary blood flow by infusion of mAb in the porcine S/I thrombosis model. Cyclic reductions in blood flow velocity
due to occlusive thromboses within the left anterior descending coronary artery were established and required tapping the vessel to dislodge
the thrombus (small arrows). After mAb infusion (large arrowhead), cyclic reductions were abolished for 13 min. Over the next 17 min, cyclic
reductions in flow gradually reappeared; a second infusion of mAb again decreased their frequency (not shown). BP, blood pressure in mm Hg
(1 mm Hg = 133 Pa); Doppler, blood flow velocity as measured by the Doppler effect on ultrasound in kilohertz.
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ference with this binding is probably responsible for the
antithrombotic effect. Since this glycoprotein also binds
vWF, it too may contribute to the antithrombotic effect.
When mAb binds with vWF, the vWF activities lost (Table
1) are those that bind to glycoprotein Ib (12).
The finding of in vitro deagglutination of vWF-induced
platelet aggregates (Fig. 1B) by mAb correlated nicely with
the observation that the mAb caused the reestablishment of
stable blood flow in coronary arteries occluded with thrombi
(Fig. 6). This effect of the mAb, along with its effect in
preventing thrombosis, suggests that it may have clinical
applications in patients with acute coronary thrombosis.
Most drugs designed to prevent platelet thrombosis are
antiplatelet agents. In contrast, mAb, acting as it does on the
vWF molecule, should not affect the intrinsic functions ofthe
circulating platelets in treated subjects.
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